P&G Files A Third Suit To Stop Generic Actonel
In another attempt to block a generic version of its osteoporosis drug Actonel from the market, Procter & Gamble fired off a third suit against Teva Pharmaceutical Industries Ltd. Friday, again...To view the full article, register now.
Already a subscriber? Click here to view full article